Skip to Content
Merck
CN
  • Characterization of multiple interactions between the envelope E protein of SARS-CoV-2 and human BRD4.

Characterization of multiple interactions between the envelope E protein of SARS-CoV-2 and human BRD4.

STAR protocols (2023-01-04)
Mohamad Zandian, Suk Min Jang, Catherine Lachance, Arpan Acharya, Siddappa N Byrareddy, Jacques Côté, Tatiana G Kutateladze
ABSTRACT

The SARS-CoV-2 envelope (E) protein hijacks human BRD4 (bromodomain and extra-terminal domain protein 4). Here, we describe a protocol to characterize the interaction of the acetylated E protein with BRD4 in vivo. We detail steps to use NMR spectroscopy to map the binding interface and include steps to monitor the effect of BRD4 inhibitors in SARS-CoV-2-infected human lung bronchial epithelial cells. This approach could be applied to study interactions involving other viral and human proteins. For complete details on the use and execution of this protocol, please refer to Vann et al. (2022).1.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Ethylenediaminetetraacetic acid disodium salt dihydrate, BioUltra, 98.5-101.5%
Sigma-Aldrich
Phenylmethanesulfonyl fluoride, ≥98.5% (GC)
Sigma-Aldrich
ANTI-FLAG® M2-Peroxidase (HRP) antibody, Mouse monoclonal, clone M2, purified immunoglobulin, buffered aqueous glycerol solution
Sigma-Aldrich
Sodium butyrate, ≥98.5% (GC)
Millipore
ANTI-FLAG® M2 Affinity Gel, purified immunoglobulin, buffered aqueous glycerol solution